Mangalam Drugs & Organics Limited has disclosed subsequent defaults on its bank loan accounts under SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The pharmaceutical company reported overdue amounts totaling ₹1558.05 lacs across two cash credit facilities as of April 15, 2026.

Default Details and Timeline

The company's disclosure reveals defaults on cash credit facilities with two major banks, both exceeding the regulatory threshold of 30 days. The defaults began in October 2025 and have continued into April 2026.

Regulatory Compliance and Disclosure

The disclosure was made under Regulation 30, Part A of Schedule III of SEBI regulations, which mandates listed entities to report defaults on debt obligations without applying materiality guidelines. The regulation specifically covers situations where outstanding balances in revolving facilities like cash credit remain continuously in excess of sanctioned limits for more than thirty days.

Managing Director Govardhan M. Dhoot signed the regulatory filing dated April 16, 2026, addressed to both BSE Limited and National Stock Exchange of India Limited. The company's scrip code on BSE is 532637, while it trades under the symbol MANGALAM on NSE.

Management Response

The company has acknowledged the default situation and indicated efforts toward resolution. Management stated they are making arrangements to pay the overdue amounts as soon as possible. Chief Financial Officer Jeevan Dalvi also signed internal documentation confirming the default status.

Previous Disclosures

The current disclosure references a previous letter dated February 16, 2026, suggesting this is part of ongoing communication regarding the company's loan default situation. The subsequent disclosure indicates the defaults have persisted beyond the initial reporting period.

The company maintains its registered office at Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G.P.O. Mumbai, and operates as a WHO-GMP accredited pharmaceutical manufacturer with CIN L24230MH1972PLC116413.

Shree Kishoriju Trading and Investments Private Limited, a promoter group entity of Mangalam Drugs & Organics Limited, has released pledged shares from encumbrance in compliance with SEBI regulations. The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited on 10/04/2026.

Share Release Details

The promoter entity released 1,500 shares from pledge on 06/02/2026, which were previously encumbered as security for debt with M/s Badjate Stock Broking Private Ltd. This transaction represents a release of encumbrance rather than a sale or transfer of shares.

Shareholding Impact

The release has resulted in a marginal change in the promoter's encumbered shareholding pattern. Shree Kishoriju Trading continues to hold 5,07,099 shares, representing 3.20% of Mangalam Drugs & Organics' total share capital.

Regulatory Compliance

The disclosure was made pursuant to Regulations 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The document was signed by Smita A. Dhoot, Director of Shree Kishoriju Trading and Investments Private Limited, bearing DIN 01867999.

Corporate Information

Shree Kishoriju Trading and Investments Private Limited operates under CIN U65990MH1981PTC024003 with its registered office located at Film Center, 2nd floor, unit no 21A, 68 Tardeo Road, Mumbai - 400034. The company maintains its promoter status in Mangalam Drugs & Organics Limited, which trades on both BSE (Scrip Code: 532637) and NSE (Symbol: MANGALAM).